Recent gains in the fight against malaria are threatened by the emergence and spread of artemisinin and partner drug resistance in Plasmodium falciparum in the Greater Mekong Subregion (GMS). When artemisinins are combined with a single partner drug, all recommended artemisinin-based combination therapies have shown reduced efficacy in some countries in the GMS at some point. Novel drugs are not available for the near future. Triple artemisinin-based combination therapies, combining artemisinins with two currently available partner drugs, will provide one of the last remaining safe and effective treatments for falciparum malaria that can be deployed rapidly in the GMS, whereas their deployment beyond the GMS could delay or prevent the global emergence and spread of resistance to currently available drugs.

在大湄公河次区域（GMS）的恶性疟原虫中，青蒿素的出现和扩散以及伴侣的耐药性威胁着抗击疟疾的最新进展。当青蒿素与单一伴侣药物联合使用时，在某些国家/地区，所有推荐的基于青蒿素的联合疗法在某些国家/地区的GMS中均显示出降低的疗效。新药在不久的将来不可用。以青蒿素为基础的三联疗法将青蒿素与两种目前可用的配伍药物结合起来，将为恶性疟疾提供最后一种安全有效的治疗方法，该方法可以在GMS中快速部署，而在GMS之外的部署则可能会延迟或预防这种疾病。全球对现有药物耐药性的出现和扩散。